A quadruplet regimen comprising the monoclonal antibody elotuzumab plus weekly carfilzomib, lenalidomide and dexamethasone conferred a 72% 3-year PFS rate among patients with newly diagnosed multiple myeloma, phase 2 trial results showed.
Data from the study published in JAMA Oncology suggest that use of a minimal residual disease (MRD)-guided regimen can limit treatment exposure while maintaining deepened responses to therapy without the need for front-line autologous stem cell transplant (ASCT), the investigators noted.
Results of randomized studies have shown that quadruplet regimens
